314 related articles for article (PubMed ID: 32997864)
1. A case report on the use of topical cysteamine 5% cream in the management of refractory postinflammatory hyperpigmentation (PIH) resistant to triple combination cream (hydroquinone, topical corticosteroids, and retinoids).
Mathe N; Balogun M; Yoo J
J Cosmet Dermatol; 2021 Jan; 20(1):204-206. PubMed ID: 32997864
[TBL] [Abstract][Full Text] [Related]
2. Assessing the Effectiveness of Stabilized Cysteamine 5% Cream Compared to Hydroquinone 4%/Ascorbic Acid 3% Combination Cream in Treating Acne-induced Post-inflammatory Hyperpigmentation: A Randomized, Controlled Study.
Ahmadi K; Miri A; Bizaval Z; Sepaskhah M; Ranjbar S; Bagheri Z; Kasraee B
J Clin Aesthet Dermatol; 2024 Apr; 17(4):37-41. PubMed ID: 38638185
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the efficacy of cysteamine cream compared to hydroquinone in the treatment of melasma: A randomised, double-blinded trial.
Nguyen J; Remyn L; Chung IY; Honigman A; Gourani-Tehrani S; Wutami I; Wong C; Paul E; Rodrigues M
Australas J Dermatol; 2021 Feb; 62(1):e41-e46. PubMed ID: 32981068
[TBL] [Abstract][Full Text] [Related]
4. Topical Treatments for Melasma and Post-inflammatory Hyperpigmentation.
Sadick N; Pannu S; Abidi Z; Arruda S
J Drugs Dermatol; 2023 Nov; 22(11):1118-1123. PubMed ID: 37943277
[TBL] [Abstract][Full Text] [Related]
5. Postinflammatory and rebound hyperpigmentation as a complication after treatment efficacy of telangiectatic melasma with 585 nanometers Q-switched Nd: YAG laser and 4% hydroquinone cream in skin phototypes III-V.
Lueangarun S; Namboonlue C; Tempark T
J Cosmet Dermatol; 2021 Jun; 20(6):1700-1708. PubMed ID: 33002283
[TBL] [Abstract][Full Text] [Related]
6. Skin lightening preparations and the hydroquinone controversy.
Draelos ZD
Dermatol Ther; 2007; 20(5):308-13. PubMed ID: 18045355
[TBL] [Abstract][Full Text] [Related]
7. Topical treatment for postinflammatory hyperpigmentation: a systematic review.
Tan MG; Kim WB; Jo CE; Nabieva K; Kirshen C; Ortiz AE
J Dermatolog Treat; 2022 Aug; 33(5):2518-2526. PubMed ID: 34525885
[TBL] [Abstract][Full Text] [Related]
8. Significant therapeutic response to cysteamine cream in a melasma patient resistant to Kligman's formula.
Kasraee B; Mansouri P; Farshi S
J Cosmet Dermatol; 2019 Feb; 18(1):293-295. PubMed ID: 30537063
[TBL] [Abstract][Full Text] [Related]
9. Melasma and Post Inflammatory Hyperpigmentation: Management Update and Expert Opinion.
Sofen B; Prado G; Emer J
Skin Therapy Lett; 2016 Jan; 21(1):1-7. PubMed ID: 27224897
[TBL] [Abstract][Full Text] [Related]
10. Topical treatments for melasma and postinflammatory hyperpigmentation.
Lynde CB; Kraft JN; Lynde CW
Skin Therapy Lett; 2006 Nov; 11(9):1-6. PubMed ID: 17075653
[TBL] [Abstract][Full Text] [Related]
11. Postinflammatory hyperpigmentation: A comprehensive overview: Treatment options and prevention.
Chaowattanapanit S; Silpa-Archa N; Kohli I; Lim HW; Hamzavi I
J Am Acad Dermatol; 2017 Oct; 77(4):607-621. PubMed ID: 28917452
[TBL] [Abstract][Full Text] [Related]
12. Prophylaxis of Post-Inflammatory Hyperpigmentation From Energy-Based Device Treatments: A Review [Formula: see text].
Wong ITY; Richer V
J Cutan Med Surg; 2021; 25(1):77-86. PubMed ID: 32929988
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of hydroquinone-free skin-lightening cream for photoaging.
Dreher F; Draelos ZD; Gold MH; Goldman MP; Fabi SG; Puissegur Lupo ML
J Cosmet Dermatol; 2013 Mar; 12(1):12-7. PubMed ID: 23438137
[TBL] [Abstract][Full Text] [Related]
14. A comparative study of topical 5% cysteamine versus 4% hydroquinone in the treatment of facial melasma in women.
Lima PB; Dias JAF; Cassiano D; Esposito ACC; Bagatin E; Miot LDB; Miot HA
Int J Dermatol; 2020 Dec; 59(12):1531-1536. PubMed ID: 32864760
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Postinflammatory Hyperpigmentation With a Combination of Glycolic Acid Peels and a Topical Regimen in Dark-Skinned Patients: A Comparative Study.
Sarkar R; Parmar NV; Kapoor S
Dermatol Surg; 2017 Apr; 43(4):566-573. PubMed ID: 28114204
[TBL] [Abstract][Full Text] [Related]
16. Patterns of Over-the-counter Lightening Agent Use among Patients with Hyperpigmentation Disorders: A United States-based Cohort Study.
Saade DS; Maymone MBC; Secemsky EA; Kennedy KF; Vashi NA
J Clin Aesthet Dermatol; 2018 Jul; 11(7):26-30. PubMed ID: 30057662
[No Abstract] [Full Text] [Related]
17. Topical Stabilized Cysteamine as a New Treatment for Hyperpigmentation Disorders: Melasma, Post-Inflammatory Hyperpigmentation, and Lentigines.
Desai S; Hartman C; Grimes P; Shah S
J Drugs Dermatol; 2021 Dec; 20(12):1276-1279. PubMed ID: 34898155
[TBL] [Abstract][Full Text] [Related]
18. Trichloroacetic acid model to accurately capture the efficacy of treatments for postinflammatory hyperpigmentation.
Lyons AB; Kohli I; Nahhas AF; Braunberger TL; Mohammad TF; Nicholson CL; Nartker NT; Modi K; Matsui MS; Lim HW; Hamzavi IH
Arch Dermatol Res; 2020 Dec; 312(10):725-730. PubMed ID: 32253506
[TBL] [Abstract][Full Text] [Related]
19. A Randomized, Investigator-Blinded Comparison of Two Topical Regimens in Fitzpatrick Skin Types III-VI With Moderate to Severe Facial Hyperpigmentation.
Vanaman Wilson MJ; Jones IT; Bolton J; Larsen L; Wu DC; Goldman MP
J Drugs Dermatol; 2017 Nov; 16(11):1127-1132. PubMed ID: 29141061
[TBL] [Abstract][Full Text] [Related]
20. Acne in ethnic skin: special considerations for therapy.
Callender VD
Dermatol Ther; 2004; 17(2):184-95. PubMed ID: 15113286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
